Skip to main content

Advertisement

Table 3 Summary of irAEs

From: Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

irAE Patients, n (%)
Any grade Grade 3/4
Total 286 (33) 55 (6)
Pruritus 58 (7) 1 (<1)
Rash 64 (8) 4 (<1)
Diarrhoea 60 (7) 19 (2)
Nausea 47 (6) 2 (<1)
Vomiting 15 (2) 2 (<1)
Constipation 7 (1) 1 (<1)
Abdominal pain 11 (1) 0
Endocrine 7 (1) 1 (<1)
Liver toxicity 19 (2) 15 (2)
Fatigue/asthenia 70 (8) 10 (1)
  1. irAEs: immune-related adverse events.